Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes
Nicolas Musi, Michael F. Hirshman, Jonas Nygren et al. · Diabetes · 2002
Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis. We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production. In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes. Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity. The increase in AMPK alpha2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment. Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations. These findings suggest that the metabolic effects of metformin in subjects with type 2 diabetes may be mediated by the activation of AMPK alpha2.
Cited by 803 works. doi:10.2337/diabetes.51.7.2074 Open-access PDF
Authors
- Nicolas Musi
- Michael F. Hirshman
- Jonas Nygren
- Monika Svanfeldt
- Peter Båvenholm
- Olav Rooyackers
- Gaochao Zhou
- Joanne M. Williamson
- Olle Ljunqvist
- Suad Efendić
- David E. Moller
- Anders Thorell
- Laurie J. Goodyear
References
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
- Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
- A Flexible System of Enzymatic Analysis
- USE OF GLUCOSE OXIDASE, PEROXIDASE, AND O-DIANISIDINE IN DETERMINATION OF BLOOD AND URINARY GLUCOSE
- Role of AMP-activated protein kinase in mechanism of metformin action
- THE AMP-ACTIVATED/SNF1 PROTEIN KINASE SUBFAMILY: Metabolic Sensors of the Eukaryotic Cell?
- Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
- Tissue distribution of the AMP‐activated protein kinase, and lack of activation by cyclic‐AMP‐dependent protein kinase, studied using a specific and sensitive peptide assay
- The AMP‐Activated Protein Kinase